DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Abroad (travel likely)RecruitingPHASE3

Conditions

AMI · STEMI · NSTEMI · Left Ventricular Dysfunction

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Department of Cardiology AP-HP Hôpital européen Georges - Pompidou, Paris, France
Contact: Study coordinator (Etienne PUYMIRAT) · etienne.puymirat@aphp.fr · 00331.56.09.28.51

Study leads

Etienne PUYMIRAT, Pr
Principal Investigator
Assistance Publique - Hôpitaux de Paris

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes

Myocardial Infarction · Acute Coronary Syndrome · Diabetes

Abroad (travel likely)RecruitingPHASE2, PHASE3

São Paulo, Brazil

OCT Guided Magmaris RMS in STEMI

STEMI

Abroad (travel likely)Recruiting

Leuven, Belgium

Very Early PCSK9 Inhibition for Acute Myocardial Infarction

Acute Myocardial Infarction (AMI)

Abroad (travel likely)Recruiting

Shanghai, China

Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients

Acute Myocardial Infarction (AMI)

Abroad (travel likely)Recruiting

Changsha, China